/NVTAQ

NVTAQ Stock - Invitae Corporation

Q: What is the analyst price target for NVTAQ?

Analyst price target information is not currently available for NVTAQ.

Q: What is NVTAQ's market cap?

Market capitalization information is not currently available for NVTAQ.

Healthcare|Medical - Diagnostics & Research|OTC

$0.00-25.00%

$0.00 (-25.00%) • Aug 7

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for NVTAQ

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.80

52W High$1.09

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$487.00M	$516.30M	$460.45M	$279.60M	$216.82M
Gross Profit	$252.57M	$99.30M	$109.58M	$76.63M	$95.44M
Gross Margin	51.9%	19.2%	23.8%	27.4%	44.0%
Operating Income	$175.45M	$-704,646,000	$-661,503,000	$-629,572,000	$-235,666,000
Net Income	N/A	$-3,106,293,000	$-379,006,000	$-602,170,000	$-241,965,000
Net Margin	0.0%	-601.6%	-82.3%	-215.4%	-111.6%
EPS	$0.00	$-13.18	$-1.80	$-4.47	$-2.66

Company Overview

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California. On February 13, 2024, Invitae Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey.

Visit Website

Earnings History & Surprises

NVTAQ

Beat Rate

14%

Last 7 quarters

Avg Surprise

-181.2%

EPS vs Estimate

Beats / Misses

1/6

Last 12 quarters

Latest EPS

$-0.31

Q1 2024

EPS Surprise History

Q1 22

-4.3%

$-0.80vs$-0.76

Q2 22

No data

Q3 22

-100.6%

$-1.27vs$-0.63

Q4 22

+25.8%

$-0.41vs$-0.55

Q1 23

-91.4%

$-0.77vs$-0.40

Q2 23

-109.2%

$-0.78vs$-0.37

Q4 23

-981.7%

$-3.42vs$-0.32

Q1 24

-6.9%

$-0.31vs$-0.29

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2024	Jun 28, 2024	$-0.33	—	—	—
Q1 2024	Mar 6, 2024	$-0.29	$-0.31	-6.9%	✗ MISS
Q4 2023	Nov 8, 2023	$-0.32	$-3.42	-981.7%	✗ MISS
Q2 2023	Jun 30, 2023	$-0.37	$-0.78	-109.2%	✗ MISS
Q1 2023	Mar 31, 2023	$-0.40	$-0.77	-91.4%	✗ MISS
Q4 2022	Dec 31, 2022	$-0.55	$-0.41	+25.8%	✓ BEAT
Q3 2022	Sep 29, 2022	$-0.63	$-1.27	-100.6%	✗ MISS
Q2 2022	Jun 29, 2022	—	$-10.87	—	—
Q1 2022	Mar 30, 2022	$-0.76	$-0.80	-4.3%	✗ MISS
Q4 2021	Dec 30, 2021	—	$-0.90	—	—
Q3 2021	Sep 29, 2021	—	$-0.91	—	—

Frequently Asked Questions about NVTAQ

What is NVTAQ's current stock price?

Invitae Corporation (NVTAQ) is currently trading at $0.00 per share. The stock has moved -25.00% today.

What is the analyst price target for NVTAQ?

No analyst price targets are currently available for this stock.

What sector is Invitae Corporation in?

Invitae Corporation operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the OTC exchange.

What is NVTAQ's market cap?

Invitae Corporation has a market capitalization of $0.00 billion, making it a small-cap company.

Does NVTAQ pay dividends?

No, Invitae Corporation does not currently pay a dividend to shareholders.